UNDERWRITING AGREEMENT Edgewise Therapeutics, Inc. 11,627,907 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • September 14th, 2022 • Edgewise Therapeutics, Inc. • Pharmaceutical preparations • New York
Edgewise Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 11,627,907 shares of common stock, par value $0.0001 per share (the “Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 1,744,186 shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
